Clinical characteristics of the study patients
| All Patients | Patients with New Carotid Infarcts | Patients with No New Carotid Infarct | P Value | |
|---|---|---|---|---|
| Agea | 64.9 ± 16.2 | 77.2 ± 11.9 | 64.3 ± 16.2 | .14 |
| Gendera | Male 117 (36%) | Male 1 (7.1%) | Male 116 (36.8%) | .02 |
| Female 212 (64%) | Female 13 (92.9%) | Female 199 (63.2%) | ||
| Race/Ethnicity | White 166 (50.5%) | White 7 (50%) | White 159 (50.5%) | .21 |
| Hispanic 33 (10%) | Hispanic 33 (10.5%) | |||
| Asian 90 (27.4%) | Asian 4 (28.6%) | Asian 86 (27.3%) | ||
| African American 30 (9.1%) | African American 3 (21.4%) | African American 27 (8.6%) | ||
| Pacific Islander 1 (0.3%) | Pacific Islander 1 (0.3%) | |||
| Unknown 9 (2.7%) | Unknown 9 (2.8%) | |||
| Smoking history | 52 (15.8%) | 4 (28.6%) | 48 (15.2%) | .29 |
| Diabetes | 105 (31.9%) | 5 (35.7%) | 100 (31.7%) | .58 |
| Hypertensiona | 233 (70.8%) | 13 (92.9%) | 220 (69.8%) | .10 |
| Hyperlipidemia | 186 (56.5%) | 10 (71.4%) | 176 (55.9%) | .26 |
| ASAa | 191 (58.1%) | 11 (78.6%) | 180 (57.1%) | .17 |
| NSAIDs | 78 (23.7%) | 3 (21.4%) | 75 (23.8%) | 1.00 |
| Anticoagulants | 93 (28.3%) | 5 (35.7%) | 88 (27.9%) | .55 |
| Antihypertensive Rxa | 213 (64.7%) | 13 (92.9%) | 200 (63.5%) | .02 |
| Diabetes Rx | 59 (17.9%) | 4 (28.6%) | 55 (17.5%) | .29 |
| Lipid-lowering Rxa | 163 (49.5%) | 10 (71.4%) | 153 (48.6%) | .11 |
| Time elapsed between baseline brain/carotid CT/CTA and follow-up imaging (days) | 445.1 ± 442 | 390.2 ± 288 | 447.5 ± 447.7 | .48 |
| Follow-up imaging modality | CT 175 (53.2%), MRI 154 (46.8%) | CT 9 (64.3%), MRI 5 (35.7%) | CT 166 (52.7%), MRI 149 (47.3%) | .39 |
Note:—ASA indicates acetylsalicylic acid; NSAIDs, nonsteroidal anti-inflammatory drugs; Rx, treatment.
↵a Indicates variables that were different (P < .2) in the patients with new carotid infarcts and in the patients with no new carotid infarct and retained for the multivariate analysis.